EPB 004
Alternative Names: EPB-004Latest Information Update: 28 Apr 2025
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; B-cell lymphoma
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 Apr 2025 No recent reports of development identified for research development in B-cell lymphoma in USA (Parenteral)
- 18 Mar 2021 EPB 004 is available for licensing as of 18 Mar 2021. https://elpisbiopharmaceuticals.com/partnering/ (Elpis Biopharmaceuticals pipeline, March 2021)